FT. LAUDERDALE, FL--(Marketwire - November 28, 2007) - OmniComm Systems, Inc. (OTCBB: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that they will provide EDC services to Tissue Repair Company for a randomized, double-blind, placebo-controlled, comparator arm clinical trial to evaluate the safety and efficacy of Excellarate for the potential treatment of non-healing diabetic foot ulcers. Excellarate is a DNA-based topical gel that is being developed to stimulate wound healing. The study is currently enrolling patients diagnosed with Type I or II diabetes with a non-healing foot ulcer present that has failed standard of care therapy. The study will enroll approximately 210 patients at 25 U.S. medical clinics.
